Constipation Labs and Next Steps: What Tests to Ask For and When to Act

Why Constipation Happens: A Clinician's Framework

Constipation is not a single disease. It is the final common pathway of dozens of metabolic, neurologic, pharmacologic, and structural problems converging on colonic or anorectal function. Understanding the category of cause changes the workup entirely.

The Rome IV criteria define functional constipation as two or more of the following present for at least three months with onset at least six months prior: straining during more than 25% of defecations, lumpy or hard stools (Bristol types 1 or 2) more than 25% of the time, sensation of incomplete evacuation more than 25% of the time, sensation of anorectal obstruction more than 25% of the time, manual maneuvers needed to support more than 25% of defecations, and fewer than three spontaneous bowel movements per week [1]. These criteria matter because they separate occasional irregularity from a condition that warrants investigation.

Secondary causes account for a meaningful share of chronic constipation cases. Hypothyroidism alone explains 3% to 12% of referrals for chronic constipation in gastroenterology clinics [2]. Hypercalcemia from hyperparathyroidism, diabetes-related autonomic neuropathy, and medication side effects (opioids, calcium channel blockers, iron supplements, anticholinergics) together represent another large subset. The 2013 American Gastroenterological Association (AGA) technical review on constipation states: "A careful medication review and limited laboratory testing should be performed in all patients with chronic constipation before initiating empirical therapy" [3].

A practical breakdown: primary or functional constipation splits into normal-transit (most common), slow-transit, and dyssynergic defecation. Secondary constipation traces to metabolic, neurologic, or drug-induced origins. This distinction drives every decision downstream.

The Lab Panel: What Blood Work to Order First

A targeted set of blood tests can expose metabolic causes that respond to specific correction rather than laxatives. The panel is small, inexpensive, and available at any commercial lab.

TSH (thyroid-stimulating hormone) is the single highest-yield test. Overt hypothyroidism slows colonic transit measurably, and a TSH above 10 mIU/L with low free T4 has a direct treatment path: levothyroxine replacement often resolves constipation within 4 to 8 weeks [2]. Even subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) correlates with slower transit in observational data, though treatment benefit at this level remains debated.

Serum calcium screens for hypercalcemia. A corrected calcium above 10.5 mg/dL, particularly when paired with an elevated parathyroid hormone, points to primary hyperparathyroidism. A 2014 cohort study in the Journal of Clinical Endocrinology & Metabolism (N=3,200) found constipation prevalence of 24% in patients with primary hyperparathyroidism compared to 11% in age-matched controls [4].

Fasting glucose and HbA1c identify diabetes. Up to 60% of patients with long-standing diabetes report constipation symptoms, driven by autonomic neuropathy affecting the enteric nervous system [5]. A fasting glucose above 126 mg/dL or HbA1c at or above 6.5% warrants formal diabetes management before attributing constipation to a functional cause.

CBC (complete blood count) catches iron-deficiency anemia, which can signal occult GI blood loss, including from colorectal malignancy. This is especially relevant in patients over 45 or those with alarm symptoms.

Basic metabolic panel evaluates potassium and magnesium. Hypokalemia (K <3.5 mEq/L) directly impairs smooth muscle contraction in the colon. Hypomagnesemia does the same. Both are correctable with supplementation.

The AGA's 2013 guideline assigns a "strong recommendation, low quality of evidence" rating to performing these basic labs in the initial workup [3]. The logic: the tests are cheap, the downside of missing a metabolic cause is years of unnecessary laxative use, and correction of the underlying disorder frequently resolves the symptom.

Red Flags: When Constipation Demands Urgent Evaluation

Not every case of constipation warrants a slow, stepwise approach. Certain features should move a patient to the front of the diagnostic line.

Alarm features include unintentional weight loss exceeding 10 pounds, rectal bleeding or heme-positive stool, iron-deficiency anemia, new-onset constipation after age 50 with no prior screening colonoscopy, a family history of colorectal cancer or inflammatory bowel disease, and a palpable abdominal or rectal mass. The presence of any single alarm feature warrants colonoscopy before empiric therapy [3].

The U.S. Preventive Services Task Force (USPSTF) updated its colorectal cancer screening recommendation in 2021, lowering the starting age from 50 to 45 for average-risk adults [6]. For a 46-year-old presenting with new constipation who has never been screened, colonoscopy serves double duty: cancer screening and structural evaluation of the colon.

Dr. Brian Lacy, a gastroenterologist at the Mayo Clinic and co-author of the Rome IV criteria, has noted: "The presence of alarm features should always trump the temptation to treat empirically. A three-month trial of fiber in a patient with weight loss and rectal bleeding is not conservative management. It is a missed opportunity" [7]. That framing matters. Thoroughness is not the same as caution.

The Lifestyle Trial: 4 to 8 Weeks Before Escalation

For patients without alarm features and with normal labs, the evidence supports a structured lifestyle intervention before adding prescription medications.

Dietary fiber intake should reach 25 to 30 grams per day. A 2012 Cochrane systematic review of 7 RCTs (N=451) concluded that soluble fiber (psyllium) significantly increased stool frequency compared to placebo, with a number needed to treat (NNT) of 3, while insoluble fiber (wheat bran) showed inconsistent benefit [8]. Psyllium at 5 to 10 grams daily, titrated over two weeks to minimize bloating, is the best-supported option.

Fluid intake of 1.5 to 2 liters daily supports fiber's mechanism of action, though fluid alone without fiber shows minimal benefit in RCTs. Physical activity at moderate intensity for 150 minutes per week improved constipation symptoms in a 2019 randomized trial of 94 adults published in the Scandinavian Journal of Gastroenterology [9].

Scheduled toileting, specifically sitting on the toilet for 5 to 10 minutes after breakfast to exploit the gastrocolic reflex, is an underused behavioral intervention. Foot elevation with a stool to approximate a squatting posture (anorectal angle of approximately 120 degrees vs. 90 degrees when seated upright) reduced straining time by 79% in a small but frequently cited 2019 trial in the Journal of Clinical Gastroenterology (N=52) [10].

If symptoms persist after 4 to 8 weeks of this combined approach, the next step is adding an osmotic laxative while pursuing further diagnostic evaluation.

Empiric Medication: The Evidence-Based Sequence

Polyethylene glycol 3350 (PEG, sold as MiraLAX) at 17 grams daily in 8 ounces of water is the first-line pharmacologic agent. A 2010 meta-analysis in the American Journal of Gastroenterology pooling 10 RCTs (N=868) found PEG increased weekly bowel movements by 2.3 compared to placebo (95% CI: 1.5 to 3.2) with minimal adverse effects [11]. The drug is inexpensive, available over the counter, and has a favorable long-term safety profile in studies extending to 12 months.

When PEG fails or produces inadequate relief after 4 weeks at full dose, three prescription agents have strong RCT support:

Linaclotide (Linzess), a guanylate cyclase-C agonist, at 145 mcg once daily. The two key phase III trials (N=1,276 combined) demonstrated a complete spontaneous bowel movement (CSBM) responder rate of 21.2% vs. 6.2% for placebo over 12 weeks [12]. The main side effect is diarrhea, occurring in roughly 16% of patients.

Prucalopride (Motegrity), a selective 5-HT4 receptor agonist, at 2 mg once daily (1 mg in patients over 65). The pooled analysis of three phase III trials (N=1,977) showed a 24% responder rate (defined as three or more CSBMs per week) vs. 12% for placebo [13]. Prucalopride is the preferred second-line agent for slow-transit constipation specifically because it acts as a prokinetic.

Lubiprostone (Amitiza), a chloride channel activator, at 24 mcg twice daily. Phase III data (N=479) showed 57% of patients achieved a spontaneous bowel movement within 24 hours of the first dose [14]. Nausea is the dose-limiting side effect, affecting 29% of participants.

The AGA's 2013 guideline gives a "strong recommendation, high quality of evidence" rating to PEG and a "strong recommendation, moderate quality of evidence" to linaclotide for chronic idiopathic constipation [3].

Advanced Diagnostics: Anorectal Manometry, Balloon Expulsion, and Transit Studies

If two or more empiric agents fail over 8 to 12 weeks, the diagnostic question shifts from "what is causing slow transit" to "is this a pelvic floor coordination problem."

Anorectal manometry measures resting and squeeze pressures of the anal sphincter, the rectoanal inhibitory reflex, and the defecation dynamics (push pattern). A paradoxical contraction or failure to relax the puborectalis and external anal sphincter during attempted defecation defines dyssynergic defecation [15]. This diagnosis changes management entirely: laxatives will not fix a coordination problem, but biofeedback therapy will.

Balloon expulsion test is simpler. A 50 mL water-filled balloon is placed in the rectum; the patient attempts to expel it in a seated position within 60 seconds (some labs use 1 to 3 minutes). Failure to expel suggests outlet dysfunction. Sensitivity ranges from 74% to 97% depending on the protocol used [15].

Colonic transit study (radiopaque marker test or wireless motility capsule) distinguishes slow-transit constipation from normal-transit constipation. The Sitzmarks study involves swallowing a capsule containing 24 radiopaque markers and obtaining an abdominal X-ray on day 5. Retention of more than 20% of markers (five or more markers remaining) indicates slow transit [16]. The wireless motility capsule (SmartPill) provides regional transit times for the stomach, small bowel, and colon in a single test, avoiding radiation exposure.

Defecography (fluoroscopic or MRI) visualizes pelvic floor anatomy during simulated defecation. MRI defecography avoids radiation and provides soft-tissue detail for identifying rectoceles, intussusception, and excessive perineal descent. It is the preferred test when structural outlet obstruction is suspected [15].

Biofeedback for Dyssynergic Defecation: The Evidence Is Strong

When anorectal testing confirms dyssynergia, biofeedback therapy becomes the treatment of choice. Not an adjunct. The treatment.

A landmark 2006 RCT published in Gastroenterology by Rao et al. (N=77) compared biofeedback to PEG, sham biofeedback, and a combination of PEG plus sham. Biofeedback produced a 79% improvement rate in dyssynergic defecation symptoms, vs. 4% for PEG and 22% for sham. Complete spontaneous bowel movements per week increased from 1.5 to 4.6 in the biofeedback group [17]. No drug trial for constipation has produced results of this magnitude.

Dr. Satish Rao, who led that trial and directs the Digestive Health Center at Augusta University, has written: "Biofeedback retrains the neuromuscular incoordination of the pelvic floor. Unlike laxatives, it addresses the root cause rather than compensating for it" [17]. This point explains why the treatment effect persists: a 2019 follow-up study demonstrated that 67% of biofeedback responders maintained improvement at 12 months without additional therapy [18].

A typical biofeedback protocol consists of 4 to 6 sessions over 8 to 12 weeks, performed by a trained pelvic floor therapist. Availability remains a barrier in some regions. Sessions use either manometric or electromyographic sensors to provide visual feedback while the patient practices coordinated relaxation during simulated defecation.

When to Refer to Gastroenterology

A primary care physician can manage most constipation cases through the lab-workup-to-empiric-medication sequence. Referral to gastroenterology is appropriate when:

Empiric therapy with at least two agents at adequate doses for adequate durations (4 weeks each) has failed. Alarm features are present and colonoscopy is needed. Anorectal manometry or transit testing is indicated. The clinical picture suggests a motility disorder (e.g., concurrent gastroparesis, pseudo-obstruction). The patient has refractory opioid-induced constipation despite peripherally acting mu-opioid receptor antagonists (PAMORAs) such as naloxegol 25 mg daily or methylnaltrexone [19].

Surgery (subtotal colectomy with ileorectal anastomosis) is reserved for severe, confirmed slow-transit constipation refractory to all medical and behavioral therapies. It is rare. A 2015 systematic review in Diseases of the Colon & Rectum (N=32 studies, 1,009 patients) reported satisfaction rates of 84% but complication rates of 18% [20]. This is a last-resort intervention that requires exhaustive pre-surgical physiologic testing to exclude generalized dysmotility.

The workup for constipation is systematic, not complicated. Start with a focused lab panel and medication review. Try structured lifestyle measures for 4 to 8 weeks. Add PEG 3350 if needed. Escalate to prescription secretagogues or prokinetics if PEG fails. If all empiric therapy fails, pursue anorectal physiology testing to identify dyssynergia, which responds to biofeedback in roughly 70% to 80% of confirmed cases [17].